Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review
2023-02-13 | journal article; overview
Jump to: Cite & Linked | Documents & Media | Details | Version history
Documents & Media
Details
- Authors
- Dybowski, Sarah; Torke, Sebastian; Weber, Martin S.
- Abstract
- Currently, disease-modifying therapies for multiple sclerosis (MS) use 4 mechanisms of action: immune modulation, suppressing immune cell proliferation, inhibiting immune cell migration, or cellular depletion. Over the last decades, the repertoire substantially increased because of the conceptual progress that not only T cells but also B cells play an important pathogenic role in MS, fostered by the empirical success of B cell-depleting antibodies against the surface molecule CD20. Notwithstanding this advance, a continuous absence of B cells may harbor safety risks, such as a decline in the endogenous production of immunoglobulins. Accordingly, novel B cell-directed MS therapies are in development, such as inhibitors targeting Bruton tyrosine kinase (BTK).
- Issue Date
- 13-February-2023
- Journal
- JAMA Neurology
- Project
- TRR 274: Checkpoints of Central Nervous System Recovery
- Working Group
- RG Martin Weber (Translationale Neuroinflammation)
- ISSN
- 2168-6149
- eISSN
- 2168-6157
- Language
- English